Non-small cell lung cancer: HER2 oncogene status

Arkhiv Patologii

Volumn 77, Issue 2, 2015, Pages 3-9

  Kobyakov, D S ^a   Avdalyan, A M ^b   Klimachev, V V ^c   Lazarev, A F ^b   Lushnikova, E L ^d   Nepomnyaschikh, L M ^d  

^a Kogalym Town Hospital   (Russian Federation)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c ALTAI STATE MEDICAL UNIVERSITY   (Russian Federation)

^d INSTITUTE OF REGIONAL PATHOLOGY AND PATHOMORPHOLOGY   (Russian Federation)

Author keywords

HER2; In situ hybridization; Mmunohistochemistry; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADENOCARCINOMA; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PREVALENCE; PROTO ONCOGENE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; PREVALENCE; RECEPTOR, ERBB-2;

EID: 84930972185     PISSN: 00041955     EISSN: 23091266     Source Type: Journal    
DOI: 10.17116/patol20157723-9     Document Type: Article

References (17)

1. Reinmuth N., Brandt B., Kunze W.P., Junker K., Thomas M., Achatzy R. et al. Ploidy, expression of erbB1, erbB2, p53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur. Respir. J. 2000; 16: 991-6.
2. Schraml P., Kononen J., Bubendorf L., Moch H., Bissig H., Nocito A. et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin. Cancer Res. 1999; 5: 1966-75.
3. Hofmann M., Stoss O., Shi D., Buttner R., van de Vijver M., Kim W. et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52: 797-805.
4. Marx A.H., Burandt E.C., Choschzick M., Simon R., Yekebas E., Kaifi J.T. et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum. Pathol. 2010; 41: 1577-85.
5. Au N.H., Cheang M., Huntsman D.G., Yorida E., Coldman A., Elliott W.M. et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J. Pathol. 2004; 204: 101-9.
6. Cappuzzo F., Varella-Garcia M., Shigematsu H., Domenichini I., Bartolini S., Ceresoli G.L. et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J. Clin. Oncol. 2005; 23: 5007-18.
7. Cox G., Vyberg M., Melgaard B., Askaa J., Oster A., O'Byme K.J. Herceptest: HER2 expression and gene amplification in nonsmall cell lung cancer. Int. J. Cancer. 2001; 92: 480-3.
8. Grob T.J., Kannengiesser I., Tsourlakis M.C., Atanackovic D., Koenig A.M., Vashist Y.K. et al. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Mod. Pathol. 2012; 25: 1566-73.
9. Hirashima N., Takahashi W., Yoshii S., Yamane T., Ooi A. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod. Pathol. 2001; 14: 556-62.
10. Hsieh C.C., Chow K.C., Fahn H.J., Tsai C.M., Li W.Y., Huang M.H. et al. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann. Thorac. Surg. 1998; 66: 1159-64.
11. Nakamura H., Saji H., Ogata A., Hosaka M., Hagiwara M., Kawasaki N. et al. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. Int. J. Cancer. 2003; 103: 61-6.
12. Pelosi G., Del Curto B., Dell'Orto P., Pasini F., Veronesi G., Spaggiari L. et al. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. Int. J. Cancer. 2005; 113: 101-8.
13. Tan D., Deeb G., Wang J., Slocum H.K., Winston J., Wiseman S. et al. HER-2/neu protein expression and gene alteration in stage I- IIIA nonsmall-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn. Mol. Pathol. 2003; 12: 201-11.
14. Kononen J., Bubendorf L., Kallioniemi A., Barlund M., Schraml P., Leighton S. et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 1998; 4: 844-7.
15. Wang S., Hossein Saboorian M., Frenkel E.P., Haley B.B., Siddiqui M.T., Gokaslan S. et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod. Pathol. 2002; 15: 137-45.
16. Marchio C., Lambros M.B., Gugliotta P., Di Cantogno L.V., Botta C., Pasini B. et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J. Pathol. 2009; 219: 16-24.
17. Hirsch F.R., Varella-Garcia M., Franklin W.A., Veve R., Chen L., Helfrich B. et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Cancer. 2002; 86: 1449-56.